SCHEMBL5534599

SCHEMBL5534599

[O]c1ccc(N2CCN(Cc3cccc(F)c3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
HSD17B10 Q99714 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.59
KDM4E B2RXH2 3/20 0.52
MAPT P10636 2/20 0.52
DRD4 P21917 4/20 0.52
DRD2 P14416 1/20 0.52
DRD3 P35462 1/20 0.52
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
FAAH O00519 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864163 0.87 DRD4 (0.70) ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL6698997 0.86 ALDH1A1 (0.60) ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL5534605 0.86 DRD4 (0.68) ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL5540751 0.83 SIGMAR1 (0.65) ALDH1A1KDM4EMAPTDRD4DRD2
SCHEMBL6698987 0.83 ITGB3 (0.60) ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL16226986 0.83 ALDH1A1 (0.82) ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2
SCHEMBL5541635 0.82 KDM4E (0.62) ALDH1A1KDM4EMAPTTSHRFAAH
SCHEMBL5544112 0.82 MAPT (0.74) KDM4EMAPTDRD4DRD2DRD3
SCHEMBL5542706 0.82 DRD4 (0.77) DRD4DRD2DRD3
SCHEMBL6233613 0.81 KMT2A (0.58) ALDH1A1MEN1KMT2AHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885MEN1 3295/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.